Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis

ConclusionsDenosumab is not cost effective for preventing secondary fractures among overall postmenopausal women in China. It is advisable to identify alternative denosumab regimens for high-risk subgroups among previously fractured postmenopausal women.

http://link.springer.com/10.1007/s40258-022-00784-3

Source: Applied Health Economics and Health Policy - January 10, 2023 Category: Health Management Source Type: research